Prostate cancer profile in Dr. Sardjito General Hospital Yogyakarta: 5th years study

Abstract

In Indonesia, there are no definite data, but Globocan shows prostate cancer
in 5th place in Indonesia in 2018. The aim of this study is to provide in
updating database of prostate cancer profile in tertiary hospital in Indonesia.
Retrospectively investigated 90 prostate cancer patients at the Sardjito General
Hospital Yogyakarta were under follow-up treatment from 2015 to 2020. The
medical record was reviewed to find data for the patient’s age, gender, prostate
volume, PSA total, testosterone level, hydronephrosis, method of diagnosis,
histopathology results, Gleason Scores, ISUP Grade, and Staging TNM. From
a total 90 subjects, showed an average age of 67 years (SD=10.4). The level of
prostate volume (TAUS), most subjects were >30 cm3 with 73 subjects (81.4%).
Of the total subjects, the median of total PSA value for diagnosis is 234.4 (94.4
– 1720.3) ng/mL with the median of total testosterone value at diagnosis is 317
(10 - 384) ng/dL. An equal between biopsy and TURP were used in method of
diagnosis and histologic finding consisting of Adenocarcinoma were found in
88 subjects (97.8%) with Gleason score > 7 in 69 subject (69.6%) and ISUP Grade
5 in 59 subject (65.6%). The staging T1c was found in 43 subjects (47.8%) and
M staging with metastasis stage was found in 55 subjects (61.1%). In contrast
with developed country, this study shows that most Indonesian prostate cancer
patients are diagnosed in metastatic stage with higher PSA level and ISUP grade.
Further encouragement in prostate cancer screening for men with symptoms
or risk factor should be considered to find more cases in lower stages for better
prognosis and survival rate.